Send to

Choose Destination
Semin Oncol. 1999 Oct;26(5 Suppl 14):74-8.

Preclinical and phase I and II trials of rituximab.

Author information

Fred Hutchinson Cancer Research Center and the Division of Medical Oncology, University of Washington, Seattle 98109, USA.


The CD20 antigen is an attractive target for antibody-directed therapy due to its stable, high-level surface expression on normal and malignant B cells. Rituximab (Rituxan; IDEC Pharmaceuticals, San Diego, and Genentech, Inc, San Francisco, CA) is an anti-CD20 chimeric monoclonal antibody that has shown single-agent activity in phase I and II clinical trials in patients with B-cell non-Hodgkin's lymphoma. This antibody has a long serum half-life and low immunogenicity. Infusional symptoms are common with the initial infusion but rare with subsequent treatments. Temporary B-cell depletion occurs but has not been associated with immunodeficiency. The mechanism of action likely includes both immune-mediated effects and direct effects. The generally mild toxicity profile and excellent single-agent activity provide the rationale for use with or following chemotherapy. Additional studies evaluating these and other combinations are under way.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center